Patients taking psilocybin to treat depression show reduced symptoms weeks after treatment following a ‘reset’ of their brain activity.
The findings come from a study in which researchers from Imperial College London used psilocybin – the psychoactive compound that occurs naturally in magic mushrooms – to treat a small number of patients with depression in whom conventional treatment had failed.
In a paper, published in the journal Scientific Reports, the researchers describe patient-reported benefits lasting up to five weeks after treatment, and believe the psychedelic compound may effectively reset the activity of key brain circuits known to play a role in depression.
Comparison of images of patients’ brains before and one day after they received the drug treatment revealed changes in brain activity that were associated with marked and lasting reductions in depressive symptoms.
The authors note that while the initial results of the experimental therapy are exciting, they are limited by the small sample size as well as the absence of a control group – such as a placebo group – to directly contrast with the patients.
Dr Robin Carhart-Harris, Head of Psychedelic Research at Imperial, who led the study, said: “We have shown for the first time clear changes in brain activity in depressed people treated with psilocybin after failing to respond to conventional treatments.
“Several of our patients described feeling ‘reset’ after the treatment and often used computer analogies. For example, one said he felt like his brain had been ‘defragged’ like a computer hard drive, and another said he felt ‘rebooted’.
“Psilocybin may be giving these individuals the temporary ‘kick start’ they need to break out of their depressive states and these imaging results do tentatively support a ‘reset’ analogy. Similar brain effects to these have been seen with electroconvulsive therapy.”
Exploring the potential of psychedelics
Over the last decade or so, a number of clinical trials have been conducted into the safety and effectiveness of psychedelics in patients with conditions such as depression and addictions, yielding promising results.
In the recent Imperial trial, the first with psilocybin in depression, 20 patients with treatment-resistant form of the disorder were given two doses of psilocybin (10 mg and 25 mg), with the second dose a week after the first. Nineteen of these underwent initial brain imaging and then a second scan one day after the high dose treatment.
Carhart-Harris and team used two main brain imaging methods to measure changes in blood flow and the crosstalk between brain regions, with patients reporting their depressive symptoms through completing clinical questionnaires.
Immediately following treatment with psilocybin, patients reported a decrease in depressive symptoms – corresponding with anecdotal reports of an ‘after-glow’ effect characterised by improvements in mood and stress relief.
‘Resetting’ brain activity
Functional MRI imaging revealed reduced blood flow in areas of the brain, including the amygdala, a small, almond-shaped region of the brain known to be involved in processing emotional responses, stress and fear. They also found increased stability in another brain network, previously linked to psilocybin’s immediate effects as well as to depression itself.
Psilocybin may be giving these individuals the temporary ‘kick start’ they need to break out of their depressive states– Dr Robin Carhart-Harris
Lead author
These findings provide a new window into what happens in the brains of people after they have ‘come down’ from a psychedelic, where an initial disintegration of brain networks during the drug ‘trip’, is followed by a re-integration afterwards.
Dr Carhart-Harris explained: “Through collecting these imaging data we have been able to provide a window into the after effects of psilocybin treatment in the brains of patients with chronic depression.
“Based on what we know from various brain imaging studies with psychedelics, as well as taking heed of what people say about their experiences, it may be that psychedelics do indeed ‘reset’ the brain networks associated with depression, effectively enabling them to be lifted from the depressed state.”
The authors warn that while the initial findings are encouraging, the research is at an early stage and that patients with depression should not attempt to self-medicate, as the team provided a special therapeutic context for the drug experience and things may go awry if the extensive psychological component of the treatment is neglected.
They add that future studies will include more robust designs and currently plan to test psilocybin against a leading antidepressant in a trial set to start early next year.
Learn more: Magic mushrooms may ‘reset’ the brains of depressed patients
The Latest on: Psilocybin
[google_news title=”” keyword=”psilocybin ” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]- Magic mushrooms are 'more effective depression treatment for older patients'on May 2, 2024 at 2:45 am
The active ingredient in magic mushrooms is a particularly effective treatment for symptoms of depression in older patients, according to a study. Scientists at the University of Oxford analysed the ...
- Magic mushrooms effective for treating depression - studyon May 2, 2024 at 2:38 am
Magic mushrooms have the potential to be an effective antidepressant, according to new research. Psilocybin - the active ingredient in magic mushrooms - has shown promise in reducing symptoms of ...
- Powerful medicineon May 1, 2024 at 4:13 pm
Local organizations are preparing to train psilocybin facilitators, but it’s not all love and light. Boulder Weekly ...
- New study supports psilocybin's potential as an antidepressanton May 1, 2024 at 3:31 pm
Psilocybin—the active ingredient in "magic" mushrooms—is a more effective treatment for symptoms of depression than controls, providing further support for its potential as an antidepressant, suggests ...
- N.J. couple admits running illegal marijuana business with help from 14-year-oldon May 1, 2024 at 2:19 pm
The couple from Somers Point in Atlantic County were charged last year after an undercover agent was repeatedly sold the business's products from a shopping center parking lot.
- Do dying people have a ‘right to try’ magic mushrooms? 9th Circuit weighs caseon May 1, 2024 at 3:00 am
In a case that could shape the future of psychedelic medicine, a palliative care physician is challenging a DEA decision that bars him from prescribing psilocybin to late-stage cancer patients.
- Timeline of Oregon’s legal psilocybin programon April 30, 2024 at 11:35 am
Oregon’s legal psilocybin program has been nearly a decade in the making. Here’s a timeline of events. Sheri and Tom Eckert formed the Oregon Psilocybin Society with the goal of putting legal ...
- Experts Discuss Botanical Psilocybin's Effect On Neurogenesis And More At Benzinga Cannabis Conferenceon April 29, 2024 at 1:42 pm
Kicking off the discussion on natural plant medicine, Elizabeth Cawley focused on botanical psilocybin, talked about the important difference between natural and synthetic products. She said that ...
- Bloom Health Club: Are psilocybin mushrooms the key to mental health?on April 29, 2024 at 10:58 am
On this episode of Bloom Health Club, we welcome Dr. Lida Fatemi, a dedicated physician and author of the groundbreaking book, “Conscious Physician Method: Conscious Life Practices & Psilocybin.” Join ...
- Success of psilocybin for depression linked to relationship with therapiston April 23, 2024 at 10:34 am
New research suggests much of the credit for the success of psilocybin for treating depression lies in the relationship between the patient and his or her therapist.
via Google News and Bing News